This article is more than 5 years old. Information may no longer be current.

Co-chair of ASN Kidney Health Initiative announced

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Raymond C. Harris

The American Society of Nephrology has announced that Raymond C. Harris Jr., MD, FASN, will serve as co-chair for its Kidney Health Initiative.

“We’re pleased that Dr. Harris will share his leadership acumen as the second ASN co-chair for KHI – he is passionate about the Kidney Health Initiative and brings a wealth of knowledge and experience,” Mark D. Okusa, MD, FASN, ASN president, said in a press release. “He brings enthusiasm and skill for engaging diverse groups to achieve a common vision.”

Harris, a professor of medicine, molecular physiology and biophysics, is the director of the Vanderbilt Center for Kidney Disease and former chief of the nephrology division of Vanderbilt University’s Medical Center in Nashville, Tennessee. He is also a past president of ASN.

With more than 90 member organizations, the KHI is the largest consortia in the kidney community. Established as a public-private partnership between ASN and the FDA, KHI connects, collaborates and innovates. It also works to advance kidney health issues and to optimize evaluation of drugs, devices, biologics and food products via patient, health care professional, scientist, industry and government collaboration.

Harris said with KHI’s previous success delivering meaningful results on individual questions related to kidney disease, harnessing KHI’s strengths will allow it to tackle bigger, more integrated projects.

“I will work with the KHI board of directors to sustain our current level of stakeholder enthusiasm, particularly the robust network among industry partners, and to support ASN’s close working relationship with the FDA,” Harris said.

Harris said KHI membership can also help define more representative patient populations for trials and further develop guidelines for clinical trials, assessing lessons learned and ways to improve going forward. Harris cited KHI’s success incorporating patients not only into advisory but also decision-making roles within the organization.

“It is important that these efforts continue. The benefits of increased outreach to more patient groups, especially those with rare diseases, is multi-fold,” he said.

Harris’s 3-year term as KHI co-chair begins on Jan. 1, 2019, with the possibility of a second, 3-year term.

Reference:

www.asn-online.org